'The Government doesn't fund hospices enough'
The government does not provide enough funding for hospices, according to the outgoing boss of a Derbyshire site who is calling for more financial support for end of life care.
Julie Heath, CEO of Treetops Hospice in Risley, told the BBC that hospices across the country were in "real difficulty" due in part to changes to National Insurance, and donations being hit by cost-of-living pressures.
The Department for Health & Social Care said it "recently announced the largest investment in hospices in a generation".
Ms Heath, who joined as a trustee 22 years ago and later became the CEO in 2018, said she would miss the job terribly but added it was "time to retire".
Back in December, the Government announced hospices in England would receive £100m of government funding over two years to improve end-of-life care.
Another £26m is planned for hospices for children and young people, which is a continuation of money previously given through a grant.
It came after hospice leaders warned they were forced to close beds due to increasing financial pressures.
But Ms Heath said the majority of hospice funds came through individual donations and sites did not have a lot of people of "high net worth" supporting them.
"There is a real challenge about finances, the Government doesn't fund us enough - we get about 18% of our money from them," Ms Heath said.
"There's the cost of living and I wish we could pay our fantastic staff more and pay them what they're worth.
"We've been hit by National Insurance, increases in the minimum wage and people don't have as much money to contribute to our services.
"It is a threat and lots of hospices are in real difficulty."
Ms Heath added the hospice for which she worked did not have the same pressures as other hospices as Treetops was not a bedded unit but it was "forever having to ask the community to support us".
Ms Heath has a background in social services and was a manager at Derbyshire County Council before being invited on to the hospice's board of trustees.
She said when she first started there were three members of paid staff - now there were 160, plus 600 volunteers and 19 shops.
She added she had seen the hospice grow from providing 20 hours of nursing care to patients each week to one which provided more than 22,000 hours to patients every year.
The hospice was also chosen to appear on BBC's DIY SOS where workers created a new children's counselling and therapy centre to provide support for bereaved young people.
"More than 1,000 people helped to build that building for free and that's one of my proudest moments... those people were there for their love for Treetops," Ms Heath added.
On the subject of advice to her successor she said: "Treetops is a business, but it's a business with the heart of a charity.
"I'd say stick to our mission, don't forget what we are for, we are here to help people at the end of their lives and for their loved ones through difficult times."
A Department for Health & Social Care spokesperson said: "Hospices carry out incredible work and that's why we recently announced the largest investment in hospices in a generation.
"This £100 million funding boost will ensure staff have the best environment to care for patients.
"We are working to make sure the sector is sustainable overall in the long term, shifting healthcare out of hospitals and into the community through our Plan for Change."
Follow BBC Derby on Facebook, on X, or on Instagram. Send your story ideas to eastmidsnews@bbc.co.uk or via WhatsApp on 0808 100 2210.
DIY SOS hospice building project gets under way
Department for Health and Social Care
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
London borough to completely ban junk food adverts amid obesity crisis
A London borough is set to ban adverts with promote "unhealthy" food in a bid to reduce levels of obesity and diabetes. Officers at Kingston Council in south-west London have drafted a report detailing the policy which will clamp down on notices of "harmful products" on all council-owned estates, assets and any advertising contracts If the scheme is approved, the council will be responsible for ensuring proposed adverts comply with the policy for all new contracts, as well as existing ones upon renewal. A joint strategic needs assessment carried out in the borough in 2023 found that instances of diabetes are on the rise, with 2,000 cases linked to obesity, the BBC reports. It further found that the top five risk factors for poor health and early deaths are tobacco, alcohol, high body mass index, poor diet and high systolic blood pressure. The report noted that the policy would "support strategic and operational plans to address the rising rates of obesity and chronic disease in the borough". Similar healthy advertising policies have been introduced by 24 local authorities across the UK, including nine London boroughs. Kingston Council's people committee will vote on whether to approve the policy on June 17.
Yahoo
a day ago
- Yahoo
King Charles Attends Trooping the Colour Amid Cancer Treatment
The annual Trooping the Colour parade celebrates the British monarch's birthday—even if their birthday isn't in June. Charles, today, is attending his third Trooping as King, ahead of his 76th birthday this November. Like last year, King Charles did not ride on horseback in the parade, instead choosing to ride in a carriage alongside Queen Camilla. Trooping the Colour is taking place as King Charles continue to receive treatment for cancer. Buckingham Palace has never revealed what type of cancer the king has, only specifying it is not prostate cancer, and has shared infrequent updates on his health since the initial diagnosis announcement last February. This past March, the King was briefly hospitalized, according to the Palace, when he experienced side effects 'following scheduled and ongoing medical treatment for cancer.' Prince Harry also recently sparked concern about Charles's health when he commented to the BBC that he doesn't know how much longer his father has to live. 'He won't speak to me because of this security stuff. But it would be nice to reconcile,' the Duke of Sussex revealed. Yet, in May, a senior royal aide said the King is dealing 'incredibly well' with cancer, adding, 'The thing you learn about this illness is that you just manage it and that's what he does. Medical science has made incredible advances and I genuinely see no difference in him. As long as you just do what the doctors say, just live your life as normal as possible... that's exactly what he is doing.' You Might Also Like 12 Weekend Getaway Spas For Every Type of Occasion 13 Beauty Tools to Up Your At-Home Facial Game
Yahoo
3 days ago
- Yahoo
World-first blood cancer therapy to be given on NHS
A "Trojan horse" therapy that sneaks toxic drugs inside cancer cells is being made available on the NHS in England in a world first. It can halt the blood cancer myeloma for nearly three times longer than current therapies. The drug is an advanced form of chemotherapy that hits cancer with a bigger dose, while reducing side-effects. Paul Silvester, one of the first people to get it, says the therapy has been "life-changing" and he's now planning history-themed adventures. Myeloma – also known as multiple myeloma – affects part of the immune system called plasma cells. These are made in the spongey bone marrow in the centre of our bones. Paul, who is 60 and from Sheffield, was diagnosed nearly two years ago after the cancer led to broken bones in his back. He had a bone marrow transplant last year, but relapsed around Christmas. He has since been on the new therapy – called belantamab mafodotin – as part of an early access scheme. Within weeks he was in remission. Other treatments could have left him isolating in his bedroom for months, so Paul says the therapy "is absolutely life-changing" and was "creating that opportunity to enjoy" life. Visiting Hadrian's Wall is next on the agenda for history buff Paul; and he's looking forward to one of his daughters graduating later this year. "Most people say 'you look really really well'... I have a good normal life," he told the BBC. Paul's therapy - belantamab mafodotin – is a lethal chemotherapy drug that has been bound to an antibody, similar to the ones the body uses to fight infection. However, these antibodies have been designed to spot markings on the outside of plasma cells. So they travel to cancerous cells, stick to the surface and are then absorbed. Once inside they release their toxic payload, to kill the cancer. The therapy is named Trojan horse therapy after the siege of the city of Troy in Greek mythology, when a giant wooden horse was used to smuggle soldiers into the city. Myeloma cannot be cured, but clinical trials last year showed the Trojan horse therapy halted the cancer for three years, compared to 13 months with current therapies. Prof Peter Johnson, the national clinical director for cancer at NHS England, said the difference was "life-changing". He told me: "This is a really important development for people with myeloma, because although we may not be able to cure the illness, giving them time free of the disease and free of the symptoms is really important. "We've seen in the last few years that using antibodies to deliver chemotherapy drugs directly into cells can make a big difference for a variety of different types of cancer." Around 33,000 people are living with myeloma in the UK. The new drug will be used when the first-choice therapy fails, so around 1,500 patients a year could benefit. The decision comes after a review by the National Institute of Health and Care Excellence (NICE) concluded the drug was cost-effective for NHS use. NICE recommendations are normally adopted in England, Wales and Northern Ireland while Scotland has its own process. The therapy is kinder than other cancer treatments, but is not free from side-effects. After a cancer cell has been destroyed, the remaining chemotherapy drug will leak into the body. This can cause dry eyes and blurred vision. The technical name for these drugs is an antibody-drug-conjugate. This therapy was developed by GSK in the UK with early research taking place in Stevenage and the first clinical trials in London. Prof Martin Kaiser, team leader in myeloma molecular therapy at the Institute of Cancer Research, said these "are very smart drugs" and the difference in side effects compared to other drugs "is really remarkable". While myeloma is still considered an incurable cancer, Prof Kaiser says drugs like this are "an important step towards a functional cure" and he thinks long-term remission will go "above 50% in the next five years". Antibody drug conjugates are being developed for a range of cancers. The limitation is being able to design an antibody that can target the cancer alone. There is one that can target some types of breast cancer. Research is already taking place on stomach and bowel cancer. Shelagh McKinlay, from the charity Myeloma UK, said the approval would "transform the lives of thousands" and it was "fantastic to see the UK at the forefront of myeloma treatment". Health Minister Karin Smyth, said: "This ground-breaking therapy puts the NHS at the forefront of cancer innovation." Exercise improves colon cancer survival, major study shows Breakthrough cancer drug doubles survival in trial
